30 Oct 2005

New Gates Funding Will Enable MVI and GSK Biologicals to Complete Development of World’s Most Advanced Malaria Vaccine Candidate Collaborators Will Expand Clinical Evaluation of Malaria Vaccine Candidate in Infants in Preparation for Large-Scale Efficacy Trials